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Introduction: Allograft transplantation is an effective end-point therapy to replace the function of 
an impaired organ. The main problem associated with allotransplantation is the induction of 
immune responses that results in acute and chronic graft rejection. To modulate the response of 
the immune system, transplant recipients generally take high dose immunosuppressant drugs for 
life. These drugs are associated with serious side effects such as infection with opportunistic 
pathogens and the development of neoplasia.  
Areas covered: We reviewed the obstacles to successful transplantation and PLGA-based 
strategies to reduce immune-mediated allograft rejection.  
Expert opinion: Biomaterial-based approaches using micro- and nanoparticles such as poly 
(lactic-co-glycolic acid) (PLGA) can be used to achieve controlled release of drugs. This approach 
decreases the required effective dose of drugs and enables local delivery of these agents to specific 
tissues and cells, whilst decreasing systemic effects. 
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Article highlights 
• One of the main concerns of allotransplantation is overcoming and modulating immune 
responses.  
• Common immunosuppressant drugs cause adverse effects because of their general and non-
specific impacts.  
• The development of nano/microparticles such as PLGA, which allows controlled release and 
targeted delivery of these drugs presents a promising therapeutic approach.  
• The lower toxicity of drug-encapsulated PLGA nanoparticles compared with the soluble form 
and the potential for combination therapy with additional induction therapies are the main 
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Abbreviation  
aAPCs: Artificial antigen-presenting cells (APCs) 
CsA: Cyclosporine A 
CMV: Cytomegalovirus  
DAMPs: Danger associated molecular patterns  
ECDI: 1-ethyl-3-(30-dimethyl aminopropyl)-carbodiimide  
HGMB1: Heat-shock proteins  
IRI: Ischemia-reperfusion injury  
IL: Interleukin  
IMPDH2: Inosine 88 monophosphate dehydrogenase-2  
IBD: Inflammatory bowel disease  
LIF: Leukemia Inhibitory Factor  
MNPs: Micro and nanoparticles  
MMF: Mycophenolic acid  
MHC: Major histocompatibility complex 
PLGA: Poly (lactic-co-glycolic acid 
PRRs: Pattern recognition receptors  
PD‐L1: Programmed death ligand‐1 
RA: Retinoic acid  
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1. History of Transplantation 
Most common organs and tissues (including transplanted kidneys, liver, heart, corneal and 
musculoskeletal grafts) have been successfully transplanted. Long-term acceptance of allografts is 
the main goal of clinical transplantation. The obstacles to successful transplantation are 
immunologically mediated damage (termed allograft rejection), and adverse effects of 
immunosuppressant drugs [1]. Improvement in surgical techniques occurred in parallel with 
developments in the understanding of the immune mechanisms mediating allograft rejection and 
these developments enabled the first kidney transplant in 1963 [2-5]. The promise of improved 
immunosuppression and increased survival opened the door to the transplantation of other organs, 
including the heart, liver, pancreas, lung and small bowel. [6-10]. 
During the past two decades, several immunosuppressive drugs have minimized the risk of 
allograft rejection, but all current immunosuppressive drugs lack specificity, resulting in severe 
side effects [11]. The frequency of all organ graft rejection is approximately 15 % during the first 
six months after transplantation. For these reasons, physicians and immunologists are making 
every effort to develop new approaches to decrease the side effects of immunosuppressive drugs 
in organ transplants or to eliminate the use of these drugs by inducing allograft-specific tolerance 
mechanisms [12].  
 
2. Mechanism of allograft rejection 
Despite advances in techniques to limit transplant rejection, allograft rejection mechanisms have 
not yet been completely explained.. [13]. Clinical rejection is classified according to the length of 
time after the transplant at which rejection happens, as follows: 
 
2.1. Hyper-acute rejection 
Hyper-acute rejection is uncommon and occurs in within minutes to hours after transplantation in 
vascularized grafts such the kidney and heart.  Rejection occurs due to alloantibodies preformed 
by the recipient which can be classified into two subclasses: 1) preformed IgG antibodies against 
MHC class I molecules, these are most common in sensitized individuals especially after 
transplantation, repeated transfusions, or multiple pregnancies. 2) Pre-existing "natural" IgM 
alloantibodies against non-self carbohydrate determinants, such as alloantibodies against ABO 
blood group antigens [14,15].  
2.2. Acute rejection 
Acute rejection, occurs days to months after transplantation, and is mediated by both humoral 
(alloantibody ) and cell (CD4+ T cells and CD8+ T cells)-mediated immune reactions, mainly in 
response to MHC antigens that are present on vascular endothelial and parenchymal cells. [16]. 
2.3. Chronic rejection 
Chronic rejection [17] is the main cause of allograft failure, and occurs months or years following 
transplantation. The exact pathogenesis of chronic rejection is unknown. HLA incompatibility, 
ischemic damage, and the number and the severity of acute rejection events and infections are the 
main risk factors for the development of chronic rejection [18,19]. Current immunosuppressant 
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drugs cannot entirely prevent chronic rejection, so the new generation of agents could help to 
improve survival of graft by vasculoprotective effects,  preventing neointima formation [20,21] 
and enabling the clinical induction of tolerance [22]. 
 
3. The mechanisms of immune-mediated rejection 
3.1. Ischemia-Reperfusion Injury 
After removal of the allograft from the donor, the graft becomes ischemic. This situation would 
ultimately result in necrosis of the tissue if it was not implanted into a recipient, and the blood 
supply restored (reperfusion). Ischemia-reperfusion injury (IRI) encompasses the damage that 
occurs to the tissue whilst it is ischemic, and damage which occurs at reperfusion.  
3.2. Alloreactive- T cell activation mechanisms 
In this field, three mechanisms have been described that result in allograft rejection, including 
direct, semi-direct and indirect presentation.  
3.2.1. Direct presentation: 
Donor APCs, mainly resident DCs in the allograft which have allogenic MHC molecules, migrate 
to the draining lymph nodes where they present alloantigens to alloreactive recipient T cells. This 
results in the development of helper- and cytotoxic- T cells which play a central role in the rejection 
process [23]. 
3.2.2. Indirect presentation: 
Recipient DCs process alloantigens (donor MHC molecules) as exogenous antigens in a self-MHC 
context and present various alloantigens from the graft to alloreactive recipient T cells.  This 
pathway is responsible for chronic rejection and hence is the main reason for organ failure, which 
cannot be prevented or treated at present. [24-26] (Figure 1). 
3.2.3. Semi-direct presentation 
Donor membrane fragments which carry MHC class I molecules can transfer to recipient APCs 
[24,27]. The semidirect presentation involves cell-to-cell interaction through the release and 
uptake of MHC-I-containing vesicles [28] 
  
4. Mechanisms of clinical immunosuppression drugs and their side effects 
As explained above, immunosuppressant drugs are essential for transplant recipients, and play a 
vital role in maintaining the integrity of grafts. Nevertheless, they have some serious side effects, 
described below. 
 
4.1. Mycophenolic acid (MMF) 
MMF has an anti-proliferative immunosuppressant effect through the inhibition of inosine 88 
monophosphate dehydrogenase-2 (IMPDH2), which is the rate-limiting enzyme in the de novo 
synthesis of guanine.  Gastritis, leukopenia, esophagitis, and opportunistic CMV infection are a 
complication of MMF therapy. 
 
4.2. Calcineurin inhibitors—FK506 and Cyclosporine A 
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CsA is a calcineurin inhibitor which decreases the expression of pro-inflammatory cytokines, 
resulting in the suppression of the effector function of T cells.CsA has some severe side effects 
such as diabetes, end-organ toxicity, neurotoxicity and hypertension [29]. FK506 or tacrolimus is 
a next-generation calcineurin inhibitor with a potency 10–200 times greater than that of  CsA [30]. 
Unfortunately, FK506 treatment is associated with a range of side effects, including nephrotoxicity 
and neurotoxicity, opportunistic infection and diabetes [31-33]. 
 
4.3. Rapamycin  
Rapamycin or sirolimus inhibits the mammalian rapamycin target (mTOR), thereby regulating cell 
proliferation by suppressing cell cycle transition from the G1 to the S phase and by preventing 
protein synthesis [34]. In addition to suppression of effector T cells, rapamycin can shift DCs 
toward a more tolerogenic phenotype [35-37] and drive the naïve T cells toward a regulatory T 
cell (Treg) phenotype [38-42]. Side-effects include non-specific effects on immune cells, altered 
fibroblast activity resulting in impaired wound healing, proteinuria and in some cases, diabetes 
and life-threatening pneumonitis [34,43].  
 
5. Limitations of currently used immunosuppressive drugs 
As discussed in the previous sections, the current immunosuppressive agents used in 
transplantation are associated with notable toxicity and serious side effects. Additionally, systemic 
administration (oral or intravenous) of these drugs is associated with unpredictable blood 
concentrations of the drug, resulting in toxic or non-therapeutic concentrations.  
[44-46]. 
Taken together, these limitations highlight the importance of developing new therapeutic 
technologies to improve graft outcomes in the setting of allotransplantation. Of particular interest, 
is the development of delivery systems to target therapeutic drugs to the tissues/organs of interest. 
This approach limits systemic toxicity and allows for the sustained release of agents, reducing the 
frequency with which patients are required to take their medicine [47]. 
Inducing allograft-specific immune tolerance is another field of transplant research for the 
promotion of graft survival, allowing a reduction in the dose and number of immunosuppressive 
drugs administered and maintenance of immunosurveillance. The main approach employed to 
induce transplant tolerance is the delivery of alloantigens to the graft recipient in a “tolerogenic 
form” to stimulate peripheral tolerance mechanisms to the allograft. The remaining sections of this 
review focus on nano- and microparticles, particularly PLGA, as novel approaches to targeted and 
sustained drug delivery [48]. 
 
6. Particle drug-delivery systems 
Recent research in the context of material and biomaterial science, such as micro-nano particles 
has resulted in an expansion in the availability of drug delivery systems that overcome the current 
shortcomings with conventional immunosuppression, through improved outcomes by specific 
targeting, sustained, and controlled release of drugs [49]. Particles used for drug delivery reduce 
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the systemic toxicity of immunosuppressant drugs by specific targeting to the relevant tissues 
where they maintain a therapeutic concentration of the drug.  Additionally, the most recent 
advances in this field, include biocompatible and biodegradable delivery systems that can target 
several tissue types and which can degrade in response to specific environmental conditions 
[50,51]. 
Polymeric microspheres can be loaded with drugs or proteins if they possess certain properties. 
These include biocompatibility, biodegradability and non-toxicity, protein friendly ( they do not 
induce aggregation or other structural modifications to the protein which result in 
immunogenicity), they maintain the biological activity of encapsulated-protein, exhibit high 
loading efficiency and high loading capacity of the protein, and release the drug or protein during 
contact with the release medium [50-54]. 
Various natural and synthetic biodegradable micro/nanopolymers have been employed for the 
development of drug/protein delivery systems. Characteristics of particles, such as the particle size 
may affect the tissue and cellular distribution of the micro/nanopolymers systems. In particular, 
large microparticles (around 10 μm) have a depot effect because phagocytic clearance is avoided, 
and because of their inability to cross most biological barriers. Smaller microparticles (around 2–
3 μm) can be taken up by antigen-presenting cells (APCs) but are too large for non-specific 
pinocytotic cellular uptake [51,55]. 
Therefore, current research is focused on optimizing and promoting common immunotherapies by 
integrating them into micro/nanopolymer systems. Micro/nanopolymer delivery systems have 
been studied in many fields, such as vaccine development, cancer therapy, and infectious diseases 
[49,51,56].  
Various natural and synthetic biodegradable polymers have been employed for the development 
of drug delivery systems. Poly (lactide-co-glycolide acid) (PLGA) is a widely studied polymer 
used for the improvement of polymeric drug delivery systems [57-59] (Figure 2 and 3). We will 
discuss the use of PLGA in transplant immunology. 
 
7. Use of PLGA to improve clinical outcomes compared to administration of free drug. 
As discussed above, various nanotechnologies have been employed to overcome the many 
weakness of therapy with common immunosuppressive drugs. Here, we focus on one subset of 
nanotechnology - PLGA-based nanoparticles, which confer several advantages over conventional 
approaches to drug delivery.  
Drugs-encapsulation by micro- or nano-particles of PLGA, protects the drug from degradation, 
and thereby improves stability. These particles can target and access many parts of the body, owing 
to their size, and their ability to penetrate specific tissues via the fenestrations present in the 
endothelium of inflamed tissue or overexpressed receptors on the surface of target cells. 
Additionally, drug-PLGA particles can achieve greater therapeutic efficacy compared to the 
soluble form of drugs, when nanoparticles are decorated with specific targeting agents. This 
enables drug delivery to be targeted to specific tissues, and permits the use of lower doses than 
would be needed to achieve a similar effect with soluble drugs. This approach could significantly 
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decrease the toxicity of some immunosuppressive drugs.  PLGA-based nanoparticles can improve 
pharmacokinetic and pharmacodynamic profiles of drugs via the sustained release of the 
therapeutic agent, resulting in the improved treatment efficacy [50].  
The first investigations in this field were conducted by Sanchez et al., who synthesized, 
characterized and examined CyA-loaded micro/nanospheres based on poly (DL-lactide-co-
glycolide) (PLGA) formulations [49]. The average size of the particles was 0.2-30 µm. Their 
results showed that the loading capacity of all formulation was high, and was influenced by the 
size of the microspheres. Assays monitoring the release of CyA from the microspheres showed a 
biphasic shape. The size of the microspheres and the molecular weight of PLGA, were found to 
be the main factors that affected the duration and intensity of each phase of release. Consequently, 
these factors were considered when micro/nanospheres were developed for the controlled release 
of CyA, and were optimized to provide therapeutic levels of the drug over a prolonged period [56]. 
The same investigators conducted in-vivo studies to evaluate the biopharmaceutical and clinical 
benefit of new formulations of CyA-encapsulated PLGA. Tritium-labelled CyA was loaded into 
the PLGA microparticles (30 and 1 µm) and nanoparticles (0.2 µm) which were administered 
subcutaneously to mice. The results showed that the micro/nanoparticles act as a depot, which 
releases the CyA continuously and prolongs the duration over which the drug is present in the 
blood. Furthermore, they reported that levels of the peptide in tissues (liver, spleen, kidney, and 
adipose) increased for up to several weeks after intravenous administration of a single dose of 
microencapsulated CyA. Humoral immunosuppressive responses in the week following the single-
dose intraperitoneal administration of the above-mentioned formulations were related to the in 
vivo kinetic profiles. Nanoparticles and 1-µm microparticles demonstrated a greater response 
initially (0-24 h), whereas 30-µm microparticle led to more extensive immunosuppression on day 
7. These studies demonstrated that PLGA micro/nanoparticles could be used as novel dosage 
forms, and could modulate the duration and intensity of immunosuppression, compared with free 
CyA, ultimately resulting in long term immunosuppressant therapy [56,60,61]. 
Targeted delivery and release of CsA-encapsulated PLGA nanoparticles (average diameter 260 
nm) to both cells and lymphatics have been investigated in assays by Yoshikawa et al. They 
observed that nanoparticles enable a depot release of CsA for 30 days and compared with free 
CsA, resulted in a greater local concentration of drug in the targeted tissues and cells.  Furthermore, 
they reported that the intramuscular injection of the CsA-encapsulated PLGA-nanoparticles in the 
femoral site of mice maintained the drug at high concentrations in the inguinal lymph nodes up for 
up to 1 month. The local concentration was 20 times larger than that achieved when administering 
soluble systemic CsA, whereas CsA was present at very low concentrations or was undetectable 
in the plasma [62]. 
Miyamoto et al. performed a similar study using FK506-encapsulated PLGA micro/nanoparticles 
in a rat model of liver transplantation. They reported gradual and sustained delivery of FK506 
from micro/nanoparticles for ten days, with dose‐dependent immunosuppression, after a single 
subcutaneous administration. The main site of particle uptake was the regional lymph node of the 
subcutaneously injected site. In addition, in models of liver transplantation, they observed that the 
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survival rate of a group of rats which received 4.8 mg/kg tacrolimus-loaded into PLGA 
nanoparticles was 88.6  days, which was more than other groups  (2.4 mg/kg tacrolimus-loaded 
PLGA nanoparticles , 0.16 mg/kg tacrolimus loaded PLGA NPs and 1.0 mg/kg free tacrolimus 
[63].  
Similar studies on mouse models of islet transplantation demonstrated that FK506-encapsulated 
PLGA particles improved the immunosuppressive effects on islet allograft rejection effectively, 
with limited effects on insulin secretion. They found that a single subcutaneous injection of 20 
mg/kg of tacrolimus-loaded PLGA nanoparticles could significantly prolong the survival time of 
the allogeneic islet grafts for 30 days, compared with daily tacrolimus treatment at a dose of 2 
mg/kg (11.5 days).  Furthermore, a series of administrations of tacrolimus-loaded PLGA 
nanoparticles at a dose of 10 mg/kg at 7-day intervals for 1 month notably prolonged the survival 
of islet grafts and resulted in 60% allograft acceptance. These results suggest that tacrolimus-
loaded PLGA nanoparticles could effectively suppress the immune rejection and prolong 
allogeneic islet graft survival at lower doses of drug than when free tacrolimus is used [64]. 
Lamprecht et al. evaluated the oral administration of FK506 -encapsulated PLGA nanoparticles to 
male Wistar rats with experimentally-induced colitis. FK506-nanoparticles resulted in 3-fold 
higher concentrations of the drug in inflamed regions, compared with healthy tissue, presumably 
because the nanoparticles could escape from efflux systems and mucosal metabolism. The higher 
selective adhesion and increased drug penetration into the inflamed region by drug-loaded 
nanoparticles compared with free drugs suggests that this drug delivery system could be a 
promising approach for the treatment of IBD [65]. 
Other researchers evaluated  daily oral or subcutaneous administration of tacrolimus-loaded PLGA 
or pH-sensitive Eudragit P-4135F nanoparticles in a dextran sulfate mouse model of colitis. Their 
results showed oral tacrolimus-loaded nanoparticles were less efficient in alleviating the 
experimental colitis compared to subcutaneous drug solution but were better than oral 
administration of the drug. Nanoparticles resulted in less toxicity (particularly nephrotoxicity) than 
free drug solution [66]. Tacrolimus-loaded PLGA nanoparticles entrapped in pH-sensitive 
microspheres were orally administrated in a rat model of colitis. Investigators observed that 
tacrolimus-loaded nanoparticles delivered the drug more selectivity to their site of action (colon) 
than free drug, resulting in significant improvement in the clinical activity index after three days 
of treatment [67]. Although these nanoparticles delivery systems have been developed to treat 
murine models of inflammatory bowel disease (IBD), they could be readily applied in the setting 
of small bowel transplantation. 
Rapamycin-encapsulated micro/nanoparticles delivery systems are an interesting field of allograft 
immunosuppressant therapy, since rapamycin not only inhibits T cell proliferation but also 
suppresses DC maturation and function and enhances inhibitory FoxP3+ Regulatory T cells [34-
37,68]. Several investigators have targeted delivery of rapamycin to DCs using PLGA based 
Micro/nanoparticles [69]. Jhunjhunwala et al. showed that DCs treated with rapamycin can 
suppress transplant rejection [37]. They designed rapamycin-encapsulated PLGA microparticles 
(~ 3.4 μm) and examined the release profile under intra-phagosomal (pH = 5) and extracellular 
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(pH = 7.4) conditions. Four days after phagocytosis of rapamycin-encapsulated PLGA 
microparticles, they observed that the ability of DCs to activate T cells was weak compared to DCs 
treated with soluble rapamycin. As a result, they reported specific intracellular delivery of 
rapamycin to DC cells through PLGA particles results in better efficacy of the drug, because of its 
capacity to modulate DC function in comparison with extracellular rapamycin -treated DCs [69]. 
Other similar studies were performed by Haddad et al. and Saswati et al. They synthesized 
rapamycin-encapsulated PLGA nanoparticles (average size: 280 nm). Their results showed that 
PLGA-encapsulated rapamycin reduced the expression of all maturation markers, including  MHC 
class II, CD86, ICAM-I and CD40 in DC to a greater extent than soluble rapamycin. Additionally, 
PLGA-encapsulated rapamycin suppressed the production of cytokines, and their functional 
effects on the proliferation of T cells [70,71]. 
The field of research into improving allograft survival is very extensive, and many drug-delivery 
systems have been investigated. Research on murine models of skin transplantation has 
demonstrated that mycophenolic acid (MMF)-PLGA based nanoparticles (at a 1/1000 of the dose 
of free MMF), prolonged the survival of allografts compared with daily systemic injection of 
MMF. This occurred via upregulation of the programmed death ligand‐1 (PD‐L1) and by reduced 
priming of alloreactive T cells. Furthermore, MMF based nanoparticles showed no toxicity, 
whereas recipients obtaining systemic free MMF developed iatrogenic cytopenias [72]. 
Induction of self-tolerance or acquired tolerance could be applied by cytokine pro-regulatory 
factors loaded into micro/nanoparticles based delivery systems in the setting of 
allotransplantations, through the immunoregulatory function of Treg.  Metcalfe et al. identified 
that  Leukemia Inhibitory Factor (LIF) plays a role in the regulation of transplantation tolerance in 
vivo [73]. Later, Park et al. demonstrated that LIF-loaded nanoparticles directed towards CD4+ T 
cells suppressed the IL6-driven Th17 development, developed FOXP3+ CD4+ T cell numbers in 
a non-human primate model in vitro and prolonged the survival of vascularized heart grafts in 
mice. Conversely, IL-6 encapsulated nanoparticles directed to CD4+ T cells enhanced Th17 
maturation [74,75]. 
The two main barriers to cell-based therapy of diabetes are alloimmune rejection of donor 
pancreatic islets, or stem cell-derived insulin-secreting cells and maintainance of autoimmunity 
against the diabetogenic endogenous target antigen. Nanotherapeutics could be an innovative 
approach to solving these problems. Dong et al.  developed “stealth” islets by PEGylation 
decorated with LIF-encapsulated nanoparticles (100–200 nm thick) to make islet transplantation 
viable. They showed that PEGylated nanotherapy prolonged islet viability and functionality in 
vitro/in vivo and improved long-term normoglycemia.  Furthermore, delivery of immune 
modulators such as LIF improved the viability of this innovative therapeutic strategy in the cell-
based therapy of diabetes [76]. Jhunjhunwala et al. reported that the (IL-2, TGF-β plus rapamycin)-
encapsulated PLGA nanoparticles induced the FoxP3+ Treg in human cells in vitro by releasing 
these components over 3–4 weeks [38]. 
In addition to Treg expansion, current evidence suggests that the recruitment of self-regulatory 
cells through micro/nanoparticle formulations the so-called “homing” systems could serve as an 
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effective strategy to enrich cells in a given location in order to overcome aberrant inflammation in 
the setting of transplant immunology and autoimmunity [68]. In this way, chemokine 
(chemoattractant cytokines) secretory cells induced the migration of cells which express the 
relevant receptors. For example, the chemokine CCL22 is expressed by a variety of tumor cells. It 
is an effective factor for the recruitment  of associated CCR4 receptor-expressed Tregs to the site 
of the malignancy and facilitates tumor-specific immune evasion [77]. Such strategies to recruit 
Tregs using CCL22 have helped to develop a novel therapy that employs local immunological 
hyporesponsiveness [78]. Jhunjhunwala et al. designed CCL22-loaded PLGA which released drug 
within a 3–8-week window and which promoted the site-specific recruitment of endogenous Tregs 
in vivo. In a mouse model they observed that the adoptively transferred Treg cells migrated to the 
site of microparticle injection and simultaneously delayed the rejection of transplanted allogeneic 
cells, which had been implanted at the site of microparticle injection. As a further design 
parameter, microparticles remain immobilized at the site of injection because their large size  
prevents their uptake by phagocytic cells [79]. 
DC cells also have a central role in inducing a tolerogenic condition. Lewis et al. recently designed 
two classes of PLGA microparticles including phagocytosable microparticles loaded with either 
rapamycin or retinoic acid (RA) (∼2 μm) and non-phagocytosable microparticles loaded with 
either TGFβ or IL-10(∼30 μm). Four separate combinations of microparticles (Rapa/IL-10, 
Rapa/TGFβ, RA/IL-10, and RA/TGFβ) were cultured with DCs and the results showed that the 
levels of surface expression of MHC II, CD80 and CD86 decreased in these DC resistant to LPS 
stimulation in comparison to untreated DCs and soluble proteins controls, but not single-factor 
microparticles. Furthermore, dual microparticle-treated DC cells inhibited the allogeneic T cell 
proliferation and shift T cells toward a regulatory phenotype, especially for the RA/IL-10 MPs. 
The results of this research demonstrate that combined (intracellular and extracellular) delivery of 
immunomodulatory factors (cytokines and small molecules) can promote immunoregulatory 
responses for therapeutic application in transplantation and autoimmunity by preventing 
maturation of DCs. 
As mentioned before, DCs play an important role in T-cell activation, by providing co-stimulation 
and paracrine cytokine signaling. Hence, the improvement of artificial particle-based materials 
which mimic the function of DCs to target specific T-cells for drug delivery is a topic of ongoing 
research [80,81]. Steenblock et al. synthesized artificial antigen-presenting cells on a 
biodegradable PLGA microparticle that was targeted by both recognition and co-stimulatory 
ligands (anti-CD3 and anti-CD28 ligands) for the T cell receptor and loaded with the cytokine 
interleukin-2. They reported that this artificial APC system stimulates and develops polyclonal and 
specific T-cells and improves the stimulatory capacity of these acellular systems through the 
sustained release of IL-2 in the region of T-cell contact [82]. 
The development of antigen-specific CTLs for use in clinical therapy is ongoing. Artificial 
antigen-presenting cells (APCs) have been designed and decorated with a soluble major 
histocompatibility complex–immunoglobulin fusion protein (MHC-Ig) and anti-CD3 and CD28. 
Anti-CD3 is a non-specific activator for all T cell receptors, however the presentation of specific 
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antigen by MHC-Ig provided the target specificity. These APCs induced and developed specific 
CTLs for cytomegalovirus (CMV) or melanoma which identified endogenous MHC complexes 
presented on melanoma cells. Therefore, the results of these studies confirm the importance of 
MHC-Ig–based APCs for the reproducible development of disease-specific CTLs for clinical 
approaches to adoptive immunotherapy [83]. 
Later work demonstrated that IL-2-encapsulated PLGA that coupled to anti-CD3 and CD28 as an 
aAPC could significantly affect the differentiation of CD8+ and CD4+ T cells through the 
paracrine release of IL-2. After specific contact of aAPC/T cells, paracrine delivery of IL-2 induces 
substantial accumulation of IL-2 in the synaptic contact region. The sustained release and 
accumulation of IL-2 enhanced CD25 (the inducible IL-2 Rα chain) on responding T cells and 
augments proliferation of CD8+ T cells in vitro, to a 1000-fold greater extent than equal amounts 
of bulk IL-2. This condition could promote activation-induced apoptosis in CD4+populations [84]. 
Based on the aforementioned studies, future studies will attempt to expand our knowledge of how 
these therapies could be translated for use in solid organ transplantation.  
Because of the complexity of DC/T cells interactions in the immune synapse, more research is 
necessary to develop a full understanding of these interactions. Two studies have investigated the 
principle of paracrine factor accumulation among cells and nanoparticles and also the 
thermodynamic interactions between micro/nanoparticles and cells [85,86]. These studies provide 
the required knowledge to allow the development of an effective biomimetic artificial cell 
construct for the next generation immunotherapeutics through collaboration between engineers 
and immunologists [47]. 
The numerous FDA-approved Micro/nanoparticle-based drug delivery systems (particle-loaded 
current FDA-approved drug, genetic material, and biomimetic protein delivery and aAPC) 
decrease toxicity and improve patient satisfaction by enabling controlled and sustained release of 
loaded materials. This approach of improving the efficiency of existing drugs is likely to be more 
cost-effective than the development of new drugs, and may lead to relatively rapid FDA approval 
[87-89]. Because of unresolved concerns, no micro/nanoparticle delivery system yet exists in the 
clinic for immunosuppressive drugs in any application. 
CsA encapsulated PLGA Nano/microparticles (15, 30, 45 mg/kg) were administrated daily by oral 
gavage over 28 days to Sprague Dawley (SD) rats to investigate the drug- or carrier-dependent 
change of biochemical, hematological and histological parameters. CsA-encapsulated PLGA 
Nano/microparticle did not cause any common adverse effects, but high doses (45 mg/kg) induced 
notable loss of body weight and resulted in diminished food consumption and lymphocyte numbers 
in comparison to untreated controls. This result was in agreement with the reported toxicity of 
Neoral1. CsA-encapsulated PLGA nanoparticles resulted in higher serum drug concentration than 
CsA-encapsulated PLGA microparticles, probably because the smaller particle size facilitates 
absorption. Therefore, these nanoparticles allow an increase in the therapeutic dose range without 
increasing toxicity [90]. 
A similar study demonstrated that the pharmacokinetic profile of tacrolimus formulated in PLGA 
nanoparticles was maintained for at least 14 days after a single subcutaneous or intramuscular 
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administration. It was reported that altering the PLGA/PLA ratio could help to enhance the period 
of tacrolimus release from the microspheres.  The graft survival time in this rat model of heart 
transplantation was prolonged by tacrolimus-loaded PLGA nanoparticle administration [91]. 
Bryant et al. investigated the induction of transplant tolerance in full MHC-mismatched murine 
allogeneic islet transplantation through using PLGA nanoparticle encapsulated 1-ethyl-3-(30-
dimethyl aminopropyl)-carbodiimide (donor ECDI-SP) as a synthetic, cell-free delivery system. 
Their results showed that the administration of donor antigen-encapsulated PLGA nanoparticles 
induced tolerance in approximately 20% of recipient mice by modulation of the indirect pathway 
of allorecognition. They also demonstrated that the combination of donor antigen-encapsulated 
PLGA nanoparticles with a short-term delivery of a low dose of rapamycin at the time of transplant 
significantly improved the effectiveness of  tolerance to 60% [92]. 
Ischemia-reperfusion injury (IRI) induces intragraft inflammatory responses (increase in DC 
autophagy and production of IL-6) and can result in chronic rejection.  Solhjou et al. demonstrated 
that local antagonism of the effect of IL-6 in the the donor heart, by anti-IL-6 loaded PLGA 
nanoparticles significantly reduced chronic rejection with a considerably smaller amount 
administered than other delivery approaches [93].  
Uehara et al. used MMF-loaded PEG−PLGA nanoparticles ( MMF-NPs) to deliver the MMF 
directly to the heart graft ex vivo. As previously discussed, one of the most important stimuli of 
early alloimmune reactivity and chronic allograft rejection is inflammation occurring within the 
transplanted organ from the moment of harvest. These results showed that perfusion of a donor 
mouse heart with MMF-NPs prior to transplantation suppressed cardiac transplant vasculopathy 
through repressing pro-inflammatory cytokines and chemokines within the graft.[94]  A 
summary of studies explained in this section is provided in Table 1. 
Several varieties of nanotechnology have been applied to overcome the obstacles that organ and 
cell transplantations present. This research has been extensively reviewed by Tasciotti et al . 
Nanocomposite polymer scaffolds offer an innovative approach to the synthesis of a successfully 
implanted artificial trachea. Furthermore, targeted and controlled delivery of immunosuppressive 
drugs by nanotechnology has been demonstrated to play a significant role in assuring successful 
transplants, by overcoming the problems related to drug solubility and improving drug efficacy 
in patients at a high risk of chronic rejection [95]. 
Nanotechnology could also be utilized to encapsulate therapeutic cells, such as pancreatic islets, 
blood cells, hepatocytes, and stem cells. Cell-based therapies have potential to treat a wide range 
of human diseases, such as diabetes, blood disorders, acute liver failure, spinal cord injury, and 
several types of cancer. Utilizing nanotechnology in the context of cell-based therapy can help to 
limit immune rejection and to enable the controlled release of  active agents to cells, providing a 
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8. Use of PLGA delivery systems to decrease the side-effects of common immunosuppressive 
drugs  
Many studies have been conducted to evaluate the efficiency of PLGA-micro/nanoparticle delivery 
systems compared with free immunosuppressant drugs to decrease various side effects and to 
overcome other disadvantages. 
 Wang et al. compared the effects of tacrolimus-loaded PLGA nanoparticles and free tacrolimus 
on insulin secretion. They reported lower pancreatic concentrations tacrolimus when tacrolimus-
loaded PLGA nanoparticles were used in a mouse islet allograft models, compared to the free drug. 
They additionally reported that a single injection of 30 mg/kg of free tacrolimus can suppress 
insulin secretion after 24 hours, whereas administration of the equivalent dose of tacrolimus-
loaded PLGA nanoparticles did not decrease the insulin secretion. Consequently, tacrolimus-
loaded PLGA nanoparticles prolonged islet graft survival more effectively with diminished side-
effects on insulin secretion and therefore have potential use in the context of islet transplantation 
[64]. 
In another study, Junhua et al. reported that the formulation of liraglutide (an antidiabetic agent) 
and sirolimus in islet transplanted diabetic mice resulted in normal glucose levels and sustained 
appropriate concentration of insulin. [97]. 
Meissner et al. studied nephrotoxiciy as the main adverse effect of tacrolimus in inflammatory 
bowel disease. They compared tacrolimus-loaded PLGA nanoparticles with pH-sensitive delivery 
of tacrolimus. At the end of the treatment period, they observed that nanoparticles treatment was 
associated with less-marked increases of BUN and serum creatinine [66]. 
It has been demonstrated that, compared with free drug,  nanoparticle delivery of mycophenolic 
acid, results in a lower total drug load but nevertheless, prolongs allograft survival whilst avoiding 
systemic toxic effects such as anemia and splenic cytopenia [72]. 
The results of another study with daily dosing of CsA-loaded PLGA nano/microparticles did not 
show any deleterious general health effects and no significant hematological or biochemical 
changes. However, the high dose of CsA-nano/micro-particles (45mg/kg) resulted in significant 
loss of body weight. Nevertheless, CsA-nanoparticles could be loaded with a higher dose range of 
drug and resulted in higher serum concentrations of drug without exhibiting toxicity.[90]  
Another approach to improve drug-targeting through galactosylated of PLGA nanoparticles was 
evaluated by Mistry et al. They demonstrated that tacrolimus-galactosylated PLGA nanoparticles 
provided more specific targeted delivery of tacrolimus to the liver compared with Tac- PLGA 
nanoparticles. This occurred via facilitation of receptor-mediated endocytosis via 
asialoglycoprotein receptors on liver cells. Furthermore, Tac-Gal PLGA nanoparticles were found 
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PLGA nanoparticles have also been investigated as an approach to avoid fluctuations in the 
circulating concentrations of tacrolimus. Zamorano-Leon et al. reported that a single-dose 
subcutaneous administration of tacrolimus-loaded PLGA nanoparticles resulted in notable 
immunosuppression  in rats. This occurred due to increased plasma concentrations of tacrolimus 
and a subsequent decrease of both circulating IL-2 levels and calcineurin phosphatase activity in 
mononuclear cells. Delivery of tacrolimus with PLGA nanoparticles reduced the side effects of 
gastrointestinal drug absorption and alterations of  metabolism [99]. Italia et al. demonstrated that 
the rapamycin-loaded PLGA nanoparticles exhibited higher intestinal uptake, bioavailability, and 
controlled release over 5 days. This was associated with significantly lower nephrotoxicity in rats 
compared with Sandimmune Neoral® and cyclosporine suspension [100]. 
 
9.  Drawbacks associated with PLGA drug delivery systems 
PLGA nanoparticle-based drug delivery systems have many advantages, but as with any medical 
technology, they are have limitations and problems [101,102]. The instability of encapsulated 
proteins is one of the most significant concerns when the controlled release system is loaded with 
proteins. These problems occur as a result of mechanical and chemical stresses or pH sensitivity 
during the manufacturing processes. Indeed, the dehydration process, which removes organic 
solvents during the process of encapsulation can affect the secondary structure of proteins, 
resulting in the formation of partially unfolded aggregates. Furthermore, degradation of polymers 
to lactic and glycolic acid acidifies the interior of the nanoparticles, where the protein resides, to 
as much as pH 3. These acidic conditions lead to disturbances in the structure of proteins and hence 
result in protein instability and the formation of aggregates [103,104]. Many of these issues may 
be overcome by modifying the drug release process or by modifying the carrier systems [105]. 
Various methods have been proposed to overcome these difficulties, by preventing the generation 
of the acidic microenvironment [106,107].  These methods include continuous flow-through cells 
in which the buffer is continuously replenished, membrane diffusion technique through a dialysis 
bag which removes acidic by-products, and the addition of stabilizers. The interaction of protein 
molecules with the hydrophobic surface of the polymer during processing, storage, and release 
results in incomplete release because of protein unfolding and aggregation and reduced activity of 
the protein [105,107,108]. Also, the interaction of proteins with hydrophobic polymer surfaces 
results in several interactions including adhesion, spreading and proliferation [109]. The 
hydrophilic and hydrophobic environments can be modified to decrease undesirable interactions 
between the polymeric system and proteins. This can be achieved with a  range of techniques, 
including  chemical treatment, electrospinning with suitable polymers such as Pluronics®, high-
energy radiation and high-energy modification [103,104,110]. 
The burst release of the drugs from PLGA matrices due to rapid diffusion of protein adsorbed at 
the surface of the polymer and high mobility of drug molecule during the hydration of PLGA is 
another problem associated with PLGA based nanoparticle delivery. It has been demonstrated that 
the application of certain additives, including PEG 400 can resolve this problem by improving the 
stability of encapsulated drugs [106]. Additionally, the enhanced permeability and retention (EPR) 
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effect is often misunderstood as one of the major drawbacks of this system. EPR is a heterogeneous 
phenomenon that differs from model to model, and from patient to patient. Active drug targeting 
to improve EPR is not very effective due to immunogenicity and protein adsorption following the 
introduction of targeting moieties [111]. PLGA-based nanoparticles are associated with weak drug 
loading, despite having high encapsulation efficiency. This results in increased costs of production 
and difficulties in  scaling production [112,113]. 
Another major obstacle is the poor knowledge around the various processes parameters that affect 
nanoparticle preparation [113] and particle size and morphology of the nanoparticles which are 
affected by the conditions during homogenization and droplet size distribution. The in vivo 
heterogeneous expression levels of the targeted receptor in target cells, several physiological 
barriers and in vivo different behavior of these nanoparticles can prevent the efficient accessibility 
of these nanoparticles to target tissues [114]. Consequently, in vitro and animal studies of  specific 
drug delivery systems cannot be generalized due to the complexity of drug release and other 
concerns discussed above [115]. 
 
 
10. Expert opinion 
One of the main concerns of allotransplantation is overcoming and modulating the immune 
responses to improve the survival time of allografts. Common immunosuppressant drugs such as 
corticosteroids and azathioprine cause adverse effects because of their general and non-specific 
impacts on the body. This is made worse by the fact that so many of these drugs require high doses 
and long periods of administration in order to be effective.  Therapy can therefore be improved by 
specific targeting of these agents to the immune system, especially T cells. The development of 
nano/microparticles such as PLGA, a biomimetic system, can improve drug stability and enhance 
the pharmacokinetic and pharmacodynamic profiles of drugs, enabling sustained release of the 
therapeutic agent. Decoration of  particles with specific targeting agents, can improve penetration 
into specific tissues, and enable the use of  lower doses of drugs, reducing toxicity without 
compromising the clinical effectiveness of immunosuppressant drugs. Interestingly, 
immunosuppressant drugs, immune system modulating agents (cytokines and donor-specific 
antigens to induce tolerance) can be loaded onto PLGA nano- or mocro-particles to enhance the 
efficiency of allo-transplant rejection therapy. Currently, attention is focused on the development 
of artificial antigen-presenting cells (aAPCs) which are decorated with functional groups (e.g. cell 
receptors, aptamers, antibodies, etc) to enable them to interact with specific cell types. The lower 
toxicity of drug-encapsulated PLGA nanoparticles than the soluble form, and the potential for 
combination therapy with additional induction therapies are the main advantages of 
nano/microparticle PLGA delivery systems.  
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Table 1. Studies of Drugs-loaded-PLGA MNP  
Nanoparticle Animal models/Cell 
culture 
Clinical outcomes Ref  
CSA-loaded PLGA 
MP/NP 
Mice -Nanoparticles and 1-µm 




Information Classification: General 
humoral immunosuppressive 
response initially (0-24 h) 
-30-µm microparticle led to a great 
level of immunosuppression on day 7 
CsA-loaded PLGA 
nanoparticles 
Mice  -Sustained and high level of CSA in 
the inguinal lymph nodes up 1 month 
and nearly 20 times higher than 




Rat liver transplantation 
model 
-sustained delivery of FK506 from 
micro/nanoparticles for 10 days  
-Regional lymph node of the 
subcutaneously injected site was the 





mice models  
-Improved immunosuppressant 
effects  









-Enhanced and selective drug 
delivery into the  region of 
inflammation to about 3-fold higher 




Dextran sulfate mouse 
model of colitis 
-Oral tacrolimus-loaded 
nanoparticles were less efficient in 
alleviating the experimental colitis 
compared to subcutaneous drug 
solution but preferred to oral 
administration of drug solution. 
 –Less toxicity (including 







Experimental rat model 
of colitis  
-Selective delivery of the drug to 
their site of action (colon) 
- Significant improvement in clinical 






DC cell culture -Weak ability of DC to activate T 
cells compared to DC treated with 






DC cell culture -Reduced expression of all 
maturation markers like MHC class 
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 -Suppressor effect on the cytokine 
production and functional effects on 





Murine skin transplants 
models 
-Prolonged survival of allograft 
compared with daily systemic 
injection of MMF 
 -Upregulation of programmed death 
ligand‐1 (PD‐L1) and decreasing the 
priming of alloreactive T cells  
-No toxicity observed 
[72] 
LIF-loaded 
nanoparticles (NPs)  
- Non-human primate 
cells  
-Murine Heart Allograft 
Transplant model 
 
-Suppression of IL6-driven Th17 
development  
-Increased FOXP3+ CD4+ T cell 
numbers 
 -Prolonged survival of vascularized 
heart grafts in mice 
[75] 






-Prolonged islet viability and 
functionality in vitro/in vivo 
-Improved the long-term 
normoglycemia 
 -Developed the capability of this 
innovative therapeutic strategy to 
diabetes cell therapy 
[76] 




 - In vitro FoxP3+ Treg induction in 




Mice -Promoted the in vivo site-specific 
recruitment of endogenous Tregs  
 -The adoptively transferred Treg 
cells in a mouse model migrated to 
the site of microparticle injection 
 -Delayed rejection of transplanted 
allogeneic cells which were also 









DC cell culture -Decrease of the surface levels of 
expression of MHC II, CD80 and 
CD86 on DC cells 
-Resistance of DC to LPS stimulation 
in comparison to untreated DCs and 
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- RA/IL-10 MPs:  inhibition of the 
allogeneic T cell proliferation and 
shift T cells toward a regulatory 
phenotype 
 
aAPC on a 
biodegradable PLGA 
microparticle that 
targeted by (anti-CD3 
and anti-CD28 ligands) 
and loaded by IL-2. 
Mice -Stimulates and develops the 
polyclonal and specific T-cells 
 -Improves the stimulatory capacity 
of these acellular systems through 
sustained release of IL-2 in the region 
of T-cell contacts 
[82] 
 
aAPCs:  PLGA NP that 
decorated by a soluble 
MHC-Ig and anti-CD3 
and CD28 
Cell line -Induction and development of 
specific CTLs for cytomegalovirus 




encapsulated PLGA that 
coupled to anti-CD3 and 
CD28 
Cell line - Significant differentiation of CD8+ 
and CD4+ T cells through the 
paracrine release of IL-2 
- Induction of notable IL-2 
accumulation in the synaptic contact 
region 
-Sustained release and accumulation 
of IL-2 enhanced CD25 (the 
inducible IL-2 Rα chain) on 
responding T cells 
 -Increased proliferation of CD8+ T 
cells in vitro 




CsA encapsulated PLGA 
Nano/microparticle 
Sprague Dawley (SD) 
rats 
- Serious side effects were not 
observed except at high dose (45 
mg/kg) that induce significant loss of 
body weight and diminished food 








Rat -More specific targeted delivery 
of tacrolimus to liver through 
facilitating of receptor-mediated 
endocytosis via 
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- Decreased nephrotoxicity due to 
lower distribution in the kidney  
Tacrolimus- PLGA 
nanoparticle 
Rat model of heart 
transplantation 
-The extended action of drug in 
this formulation (at least 14 days)  













-Induction of tolerance ~20% of 
recipient mice  
- Significant development of the 
tolerance effectiveness to 60% 
when combined with a short-term 
delivery of a low dose of 






Rat -Development of a notable 
immunosuppressive response 
-Increased plasma levels of 
tacrolimus  
-Decrease of both circulating IL-2 
levels and calcineurin 
phosphatase activity in 
mononuclear cells. -Reduced side 
effects of gastrointestinal drug 






Wistar Kyoto Rat Improved intestinal uptake, 
bioavailability, controlled release 
over 5 days  







-Local antagonism of the IL-6 that 
effect in the donor heart before 
transplantation – Significant 
decrease of chronic rejection with 







Heart graft under the 
ex vivo situation 
- Suppressed cardiac transplant 
vasculopathy through repressing 
intragraft pro-inflammatory 
cytokines and chemokines after 
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Figure 1. The main pathways of alloantigen recognition. In the direct presentation pathway, 
donor resident DCs in the allograft migrate to the draining lymph nodes and present their 
alloantigens to alloreactive recipient T cells that result in the cellular rejection process. In indirect 
presentation, recipient DCs process alloantigens (donor MHC molecules) as exogenous antigens 
in a self-MHC context and present to alloreactive recipient T cells.  
 
Figure 2. The development of immunosuppressant therapy in organ transplantation. 
The systemic administration of immunosuppressive drugs (Corticosteroids, Mycophenolic acid 
(MMF), Calcineurin inhibitors—FK506 and Cyclosporine and Rapamycin) was the conventional 
organ transplant treatment, but they have many serious side effects that have prompted the 
development of novel treatments based on immunomodulation or induction of tolerance. To 
develop specific and safer treatments, micro/nano particles have been decorated with targeting 
agents and loaded with immunosuppressant drugs. 
 
Figure 3. The immunomodulation drugs mechanism. These drugs can modulate the immune 
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